Press Releases

03.31.2016

Pfizer Inc. (NYSE: PFE) today issued the following statement:

03.30.2016

Pfizer and Allergan Receive Request for Additional Information from Federal Trade Commission Regarding Proposed Combination

03.30.2016

Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session

03.23.2016

Pfizer Announces European Medicines Agency Accepted for Review Its Marketing Authorization Application for XELJANZ® (Tofacitinib Citrate) for the Treatment of Moderate to Severe Rheumatoid Arthritis

03.22.2016

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

03.22.2016

Pfizer Joins The Human Vaccines Project To Help Decode The Immune System

03.18.2016

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

03.16.2016

Pfizer to Present New Data on Investigational Tofacitinib in Inflammatory Bowel Disease at the 11th Congress of ECCO

03.15.2016

Pfizer Celebrates a Year of Achievements in 2015 Annual Review

03.11.2016

XALKORI® (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer

03.09.2016

New Survey Reveals Many Living with Symptoms of Diabetic Nerve Pain Are Undiagnosed Despite Severe and Constant Pain

03.09.2016

Pfizer Commences $5 Billion Accelerated Share Repurchase